NASDAQ:CNTA
Centessa Pharmaceuticals plc
- Stock
Last Close
22.84
06/11 21:01
Market Cap
994.77M
Beta: -
Volume Today
595.10K
Avg: 172.13K
PE Ratio
−5.00
PFCF: −4.38
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|
average inventory | -8.40M - | -23.90M 184.43% | -15.00M 37.25% | |||
average payables | 4.55M - | 10.95M 140.75% | 12.83M 17.12% | |||
average receivables | 9.87M - | 21.77M 120.50% | 32.94M 51.30% | |||
book value per share | -0.32 - | 5.23 1,752.91% | 3.60 31.16% | 2.46 31.75% | ||
capex per share | -0.00 - | -0.01 515.34% | -0.00 85.51% | |||
capex to depreciation | -5.47 - | -8.68 58.66% | -0.21 97.60% | |||
capex to operating cash flow | 0.00 - | 0.01 311.83% | 0.00 81.41% | |||
capex to revenue | -0.02 - | |||||
cash per share | 0.10 - | 6.33 6,108.54% | 4.21 33.41% | 2.67 36.71% | ||
days of inventory on hand | 0.00 - | |||||
days payables outstanding | 5.30K - | |||||
days sales outstanding | 2.08K - | |||||
debt to assets | 0.48 - | 0.12 74.97% | 0.16 30.67% | 0.21 32.76% | ||
debt to equity | -0.25 - | 0.15 161.37% | 0.21 34.83% | 0.32 54.33% | ||
dividend yield | ||||||
earnings yield | -0.00 - | -0.01 108.95% | -0.36 4,926.77% | -0.75 107.45% | -0.20 73.47% | |
enterprise value | 1.54B - | 539.28M 64.99% | -34.30M 106.36% | 722.13M 2,205.19% | ||
enterprise value over ebitda | -149.76 - | -1.42 99.05% | 0.16 111.62% | -4.22 2,657.97% | ||
ev to operating cash flow | -144.90 - | -3.99 97.25% | 0.17 104.29% | -4.49 2,722.88% | ||
ev to sales | 104.97 - | |||||
free cash flow per share | -0.08 - | -0.15 82.49% | -1.44 859.66% | -2.16 50.06% | -1.68 22.41% | |
free cash flow yield | -0.00 - | -0.01 82.49% | -0.13 1,753.70% | -0.70 445.05% | -0.21 69.78% | |
graham net net | -0.34 - | 4.90 1,534.58% | 3.11 36.52% | 1.66 46.79% | ||
graham number | 1.05 - | 21.84 1,974.00% | 13.69 37.30% | 9.34 31.81% | ||
income quality | 1.15 - | 1.00 13.38% | 0.35 64.43% | 0.93 161.62% | 1.06 14.41% | |
intangibles to total assets | 0 - | 0 | 0 | 0 | 0 | |
interest coverage | -42.82 - | -27.62 35.50% | -324.05 1,073.28% | -30.18 90.69% | 17.36 157.51% | |
interest debt per share | 0.08 - | 0.82 865.22% | 0.82 0.61% | 0.68 16.84% | ||
inventory turnover | 813.14K - | |||||
invested capital | -0.25 - | 0.15 161.37% | 0.21 34.83% | 0.32 54.33% | ||
market cap | 1.54B - | 1.54B 0% | 1.06B 31.34% | 289.54M 72.65% | 765.57M 164.41% | |
net current asset value | -22.98M - | 457.00M 2,089.12% | 285.51M 37.53% | 188.37M 34.02% | ||
net debt to ebitda | 0.16 - | 1.37 779.17% | 1.56 13.87% | 0.25 83.70% | ||
net income per share | -0.07 - | -0.16 108.95% | -4.05 2,502.37% | -2.31 42.89% | -1.58 31.87% | |
operating cash flow per share | -0.08 - | -0.15 82.49% | -1.44 858.34% | -2.15 49.42% | -1.67 22.05% | |
payables turnover | 0.07 - | |||||
receivables turnover | 0.18 - | |||||
research and ddevelopement to revenue | 18.15 - | |||||
return on tangible assets | -0.94 - | -0.61 35.77% | -0.49 19.60% | -0.42 14.13% | ||
revenue per share | 0.07 - | |||||
roe | 0.49 - | -0.78 257.44% | -0.64 17.04% | -0.64 0.18% | ||
roic | 0.64 - | -0.67 204.06% | -0.52 22.20% | -0.46 11.77% | ||
sales general and administrative to revenue | 7.81 - | |||||
shareholders equity per share | -0.32 - | 5.23 1,752.91% | 3.60 31.16% | 2.46 31.75% | ||
stock based compensation to revenue | 4.27 - | |||||
tangible asset value | -22.42M - | 491.55M 2,292.19% | 336.17M 31.61% | 236.24M 29.72% | ||
tangible book value per share | -0.32 - | 5.23 1,752.91% | 3.60 31.16% | 2.46 31.75% | ||
working capital | 2.55M - | 570.44M 22,305.50% | 355.31M 37.71% | 275.71M 22.40% |
All numbers in USD (except ratios and percentages)